Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, Swisstec Ink Asian Distribution Deal

NEW YORK (GenomeWeb) – Genetic Technologies announced today that it has granted the nonexclusive distribution rights for its genetic screening tests in Asia to Swisstec Health Analytics.

Fitzroy, Australia-based Genetic Technologies offers the BrevaGenplus breast cancer risk assessment test and is developing additional cancer risk assessment products including one for colorectal cancer.

Under the terms of the deal, Swisstec will have the nonexclusive rights to distribute the tests to hospital networks in Asia. In exchange, Genetic Technologies will receive a 5 percent equity stake in Swisstec, and may acquire an additional 5 percent based on the achievement of certain undisclosed milestones. Genetic Technologies has also agreed to provide Swisstec with A$250,000 ($185,238) to facilitate its expansion into China.

The distribution deal comes a little more than month after Genetic Technologies and Swisstec agreed to form a joint venture that will develop a service platform using blockchain technology for medical services and personalized health management. As part of that collaboration, Genetic Technologies will receive a 20 percent stake in Swisstec.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more